Your session is about to expire
← Back to Search
18F-fluciclovine PET Scan for Prostate Cancer
Study Summary
This trial is for men with metastatic prostate cancer who are resistant to hormone therapy. The men will be given either abiraterone, enzalutamide, or docetaxel to see if it prolongs their life.
- Metastatic Castration Resistant Prostate Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many people are being asked to participate in this trial?
"That is correct, the online information hosted on clinicaltrials.gov affirms that this study is still recruiting patients. This particular trial was first posted on January 30th 2020 and updated as recently as October 21st 2022. The research team hopes to enroll 12 total patients at a single site."
Is this an original research project?
"There are 7 active clinical trials ongoing for 18F-fluciclovine PET Scans in 21 cities across 1 country. The first study was conducted in 2019 and involved 140 patients. The sponsor of the trial, Telix International Pty Ltd, completed Phase 2 drug approval in 2019. Since then, 5 more studies have been conducted."
Are we still recruiting people for this experiment?
"Yes, the trial is still ongoing and recruiting patients. According to the clinicaltrials.gov listing, the study was posted on 1/30/2020 and was updated as recently as 10/21/2022. They are currently searching for 12 more participants at a single site."
Does this 18F-fluciclovine PET scan have any precedent?
"There are currently 7 ongoing clinical trials involving 18F-fluciclovine PET Scans, with 1 study in Phase 3. 28 medical centres across the United States are running these trials, many of which are situated in Boston, Massachusetts."
Are there any ineligibility requirements for this research?
"Up to 12 individuals who have undergone castration and are between 18-18 years old may be enrolled in this study. There are several key eligibility requirements including: no prior exposure to life-prolonging therapies for mCRPC (with the exception of Sipuleucel-T), a life expectancy of greater than 6 months, an ECOG Performance status of 0-2, and being at least 18 years old."
Does the FDA approve of 18F-fluciclovine PET Scanning?
"While Phase 2 trials don't have data supporting efficacy, there is some evidence that 18F-fluciclovine PET Scans are safe. This gave it a score of 2."
Does this research project involve testing on elderly individuals?
"The age requirement to participate in this trial is 18-18 years old. Out of the 75 clinical trials available for patients under 18, this one is most closely matched to your needs. There are 1299 trials conducted for patients over 65."
Share this study with friends
Copy Link
Messenger